Status:
NOT_YET_RECRUITING
Ciprofol's Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients
Lead Sponsor:
First Affiliated Hospital of Wannan Medical College
Conditions:
ECMO Treatment
ARDS (Acute Respiratory Distress Syndrome)
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This study evaluates the safety and effectiveness of Ciprofol, a new sedative, in critically ill patients receiving Extracorporeal Membrane Oxygenation (ECMO), a life-support system for heart or lung ...
Eligibility Criteria
Inclusion
- Receiving ECMO therapy with an anticipated duration exceeding 72 hours;
- Requiring invasive mechanical ventilation;
- Requiring sedation and analgesia treatment.
Exclusion
- BMI \>45 kg/m²;
- Age \<18 years;
- Severe hepatic (Child-Pugh Class C) or renal failure (eGFR \<15 mL/min/1.73m²);
- History of severe psychiatric disorders;
- Pregnancy;
- Refusal to sign informed consent;
- Contraindications to midazolam and propofol use.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06934811
Start Date
May 1 2025
End Date
December 31 2026
Last Update
April 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.